News

NEWCASTLE UPON TYNE, UK, 21 January 2021. QuantuMDx today announces the appointment of Diran Guiliguian as Chief Commercial Officer. Diran has over a decade of experience working within world-leading diagnostic

NEWCASTLE UPON TYNE, UK, 22 December 2020. QuantuMDx today confirms its diagnostic assay for SARS-CoV-2 remains suitable for detecting all available virus strains, following the identification of a new variant

NEWCASTLE UPON TYNE, UK, 17 December 2020. QuantuMDx today announced it has invested over £11 million to scale up production of its flagship diagnostic device, Q-POC™ and disposable test cassette, to mass

Our Head of Assay Feasibility, Dr John Tyson presented an e-poster at ECCVID last month – the ESCMID Conference on Coronavirus. The e-poster focuses on  the independent, multi centre, clinical performance

Title: QuantuMDx SARS-CoV-2 RT-PCR Detection Assay – design, analytical and multi-centre evaluation of clinical performance White paper overview: After completing the development of our SARS-CoV-2 RT-PCR Detection Assay, QuantuMDx undertook

QuantuMDx Group today announces its SARS-CoV-2 detection assay has been CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within the European Union. QuantuMDx has now registered the

QuantuMDx Group today announces the launch of its sensitive SARS-CoV-2 assay for laboratory use, which delivers a result in approximately 70 minutes. Working with British manufacturing partner Biofortuna Limited, QuantuMDx

QuantuMDx today announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition

Improving outcomes for sepsis patients and promoting antibiotic stewardship QuantuMDx and Ontera, have announced a collaboration to create a next-generation solution for blood stream infection and drug resistance detection. The

Investigating feasibility of rapid, low-cost STI diagnostics development QuantuMDx and SpeeDx today announced a collaboration with the Foundation for Innovative New Diagnostics (FIND). The global non-profit organization drives development and

QuantuMDx has announced that Neil Butler has joined its Board as an Independent Non-Executive Director. Neil is a seasoned healthcare executive with over 20 years’ experience working in, and managing,

QuantuMDx Group Ltd has announced plans to expand the potential of its Q-POC™ technology and develop a quality control analytics system for cell and gene therapies (C&GTs), to be evaluated